Biotechnology drugs company Biocon announced a 50 per cent jump in its net profit at Rs. 509 crore for 2012-13, largely due to an exceptional income of Rs. 202 crore from the U.S. major Mylan for insulin analogues, company Chairman and Managing Director Kiran Mazumdar-Shaw said. Without the exceptional income, the consolidated net profit of Rs. 308 crore is nine per cent lower year-on-year.
The group’s revenue was up 19 per cent at Rs. 2,485 crore. The insulin analogs re-licensing or co-development model with Mylan significantly reduced the expenditure burden on Biocon.
The company shared the benefit with a 50 per cent special dividend (Rs. 2.50 per share) in addition to 100 per cent (Rs. 5 per share) dividend. Research services arm Syngene and its subsidiary Clinigene, which together clocked an income of Rs. 557 crore, were the star performers.
ADVERTISEMENT
“We are on track to being a $ 1-billion company in fiscal 2018 and touch $ 700 million by fiscal 2015,” Ms Shaw said.